Employee of the Month: Tint Wai
The Sanaria employee of the month for August 2024 is Tint T. Wai. Tint was nominated for her work quality and work ethic.
Sanaria®/Seattle Children’s PfSPZ-LARC2 Vaccine: finalist in Vaccine Industry Excellence (VIE) awards for Best Prophylactic Vaccine Award
Sanaria®/Seattle Children's PfSPZ-LARC2 Vaccine: finalist in Vaccine Industry Excellence (VIE) awards for Best Prophylactic Vaccine Award!
Sanaria is a finalist in Vaccine Industry Excellence (VIE) awards for Best Logistics Technology & Cold Chain Delivery Award
Sanaria is a finalist in Vaccine Industry Excellence (VIE) awards for Best Logistics Technology & Cold Chain Delivery Award!
Company Fishing Trip on the Bay
On August 17th, Sanaria restarted the tradition of the annual fishing trip. Fair winds and blue skies accompanied the team during the morning with a crab feast to top it off. Can't wait till next year!
Employees of the Month: Mei-Chun Chen and Ramon Dizon Jr.
The Sanaria employees of the month for October 2023 are Mei-Chun Chen and Ramon Dizon Jr.. Mei is a member of the clinical team at Sanaria and was nominated for employee of the month for her immeasurable contributions to the success of Sanaria. Ramon is a member of the Materials Management team and was nominated for employee of the month for performing his duties competently, expeditiously and with a smile, always pleasant, always willing to help and always joy to work with.
Sanaria and Seattle Children’s Research Institute host the first live i-PfSPZ-C meeting since 2019 in Seattle, WA, USA
From November 3rd-4th, 2022, Sanaria and Seattle Children's Research Institute hosted 289 researchers from 86 institutions from 28 countries in person and virtually at the International (i) - Plasmodium falciparum (PfSPZ) - Consortium (C) meeting to further a collaborative approach for presentation of data and setting research and clinical development strategies for PfSPZ based vaccines and products.
CEO of Sanaria, Dr. Stephen L. Hoffman, to present at the World Vaccine Congress on April 20th, 2022
Dr. Hoffman will be presenting at the World Vaccine Congress on April 20th, 2022.
PfSPZ Malaria Vaccine Development Progress by Sanaria in Collaboration with LMIV and MRTC, Highlighted as One of 8 Top NIH Research Projects for 2021
The U.S. National Institutes of Health (NIH) just announced eight top research highlights/projects of 2021 and Sanaria’s PfSPZ-CVac malaria vaccine development efforts in collaboration with the NIH, National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Malaria, Immunology and Vaccinology (LMIV), and the Malaria Research Training Center (MRTC) in Bamako, Mali is one of the eight. Only two were from NIAID. The other was on COVID-19. This is incredible independent recognition of Sanaria’s progress and the promise of Sanaria’s vaccine program.
Phase I Field Trial of Sanaria’s PfSPZ Vaccine Results Published in Lancet ID
On November 18th 2021, the Lancet Infectious Diseases published on a Phase I Field Trial of Sanaria's PfSPZ Vaccine efficacy in adults. The full article can be access through Pubmed here: https://pubmed.ncbi.nlm.nih.gov/34801112/
Sanaria Hosts Virtual i-PfSPZ-C Meeting
231 malaria researchers, regulators and funders from 68 institutions located in 27 different countries met virtually to share plans, insights and data, all aiming to advance the development of whole sporozoite malaria vaccines.
EUMF Investment of €12.9M in Sanaria Highlighted in BioBuzz Article
On December 2nd, 2020, the European Union Malaria Fund’s (EUMF) investment of €12.9 million in Sanaria Inc. was highlighted in an BioBuzz article written by Alex Keown.
The investment will fund the development of two Malaria vaccines, one Malaria prophylactic, and a SARS-CoV-2 vaccine. Sanaria is the first and only U.S.-based company that has received funding from the EUMF!
The full article can be accessed by this link.|
Presentations by the Bioko Island Malaria Elimination Project at the annual meeting of the American Society of Tropical Medicine and Hygiene.
Sanaria is proud to showcase posters from BIMEP that were displayed during ASTMH 2020.
Sanaria and Protein Potential Welcome Guest Speaker Dr. Golightly Who Spoke About Antiracism: Moving Beyond Good Hearts and Intentions
On September 1st, Sanaria and Protein Potential welcomed Dr. Linnie Golightly who presented on Antiracism.
OraCOV Vaccine against COVID-19
In collaboration with the University of Tübingen, Sanaria Inc. and Protein Potential, LLC are developing a vaccine against COVID-19: OraCOV
Sanaria and Protein Potential Host Shari Davis Who Facilitated a Discussion: Let’s Talk About Race & Racism
In an effort to support the end of, and continue the discussion about systemic racism, Sanaria Inc. and Protein Potential, LLC hosted Ms. Shari Davis, ACC, SPHR, SHRM-SCP, President and CEO of Venture HCM LLC. Ms. Davis gave a presentation to and facilitated a discussion with our staff about the Black Lives Matter movement.
Sanaria Celebrates Diwali
Diwali, Deepavali or Dipavali is an Indian festival of lights, which is celebrated every autumn. One of the most popular festivals in India, Diwali symbolises the “victory of light over darkness, good over evil and knowledge over ignorance.” Light is a metaphor for knowledge and consciousness. During the celebration the houses, the streets are decorated with lights. People invite friends and families and celebrate together with good foods, by exchanging gifts and burning the fire crackers. Sanaria and Protein Potential celebrated today with song, dance, and delicious food!|
